Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107485309> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W2107485309 endingPage "S74" @default.
- W2107485309 startingPage "S74" @default.
- W2107485309 abstract "4 Two-Week Treatment with Cetirizine 10 mg Is Associated with Increased Drowsiness Compared with Fexofenadine 180 mg L. E. Mansfield 1, S. Meeves 2, Y. Liao 2, G. Georges2; IEl Paso Institute for Medical Research and Development, El Paso, TX, 2Aventis Pharmaceuticals, Bridgewater, NJ. RATIONALE: This study compared the effect of treatment with fexofenadine 180 mg and cetirizine 10 mg on drowsiness and motivation in individuals with moderate to severe seasonal allergic rhinitis (SAR). METHODS: This was a multicenter, randomized, double-blind, parallel group study in which 495 subjects with moderate to severe SAR received once-daily treatment at 7 AM with either fexofenadine 180 mg (n=248) or cetirizine 10 mg (n=247) for 14 days. Changes from baseline in drowsiness and motivation were measured using a visual analog scale (VAS), which ranged from 0 (wide awake/highly motivated) to 100 (extremely sleepy/unmotivated). Drowsiness and motivation were assessed independently in patients at 7 AM, 10 AM, and 3 PM daily. RESULTS: Compared with patients treated with cetirizine, patients treated with fexofenadine had significantly less mean daily drowsiness VAS scores overall (33.71 vs. 36.39; P=0.01). Compared with patients treated with cetirizine, patients treated with fexofenadine had a trend toward greater motivation (34.29 vs. 36.75; P=0.05). Analysis of covariance, including terms for treatment and baseline values, also showed a significant difference between fexofenadine and cetirizine for change from baseline in VAS scores for drowsiness (P=0.01). Changes from baseline in mean daily drowsiness VAS scores overall for fexofenadine and cetirizine were ~5.47% and +1.03%, respectively. Changes from baseline in mean daily motivation VAS scores overall for fexofenadine and cetirizine were 6.21% and 1.05% respectively. CONCLUSIONS: tn patients with SAR, treatment with fexofenadine resulted in less drowsiness and improved motivation compared with treatment with cetirizine, as measured by VAS. Funding: Aventis Pharmaceuticals" @default.
- W2107485309 created "2016-06-24" @default.
- W2107485309 creator A5025047595 @default.
- W2107485309 creator A5042436405 @default.
- W2107485309 creator A5051911660 @default.
- W2107485309 creator A5070796582 @default.
- W2107485309 date "2003-02-01" @default.
- W2107485309 modified "2023-10-07" @default.
- W2107485309 title "Two-week treatment with cetirizine 10 mg is associated with increased drowsiness compared with fexofenadine 180 mg" @default.
- W2107485309 doi "https://doi.org/10.1016/s0091-6749(03)80176-8" @default.
- W2107485309 hasPublicationYear "2003" @default.
- W2107485309 type Work @default.
- W2107485309 sameAs 2107485309 @default.
- W2107485309 citedByCount "0" @default.
- W2107485309 crossrefType "journal-article" @default.
- W2107485309 hasAuthorship W2107485309A5025047595 @default.
- W2107485309 hasAuthorship W2107485309A5042436405 @default.
- W2107485309 hasAuthorship W2107485309A5051911660 @default.
- W2107485309 hasAuthorship W2107485309A5070796582 @default.
- W2107485309 hasBestOaLocation W21074853091 @default.
- W2107485309 hasConcept C14184104 @default.
- W2107485309 hasConcept C2776711289 @default.
- W2107485309 hasConcept C2779303165 @default.
- W2107485309 hasConcept C2779463773 @default.
- W2107485309 hasConcept C42219234 @default.
- W2107485309 hasConcept C71924100 @default.
- W2107485309 hasConcept C98274493 @default.
- W2107485309 hasConceptScore W2107485309C14184104 @default.
- W2107485309 hasConceptScore W2107485309C2776711289 @default.
- W2107485309 hasConceptScore W2107485309C2779303165 @default.
- W2107485309 hasConceptScore W2107485309C2779463773 @default.
- W2107485309 hasConceptScore W2107485309C42219234 @default.
- W2107485309 hasConceptScore W2107485309C71924100 @default.
- W2107485309 hasConceptScore W2107485309C98274493 @default.
- W2107485309 hasIssue "2" @default.
- W2107485309 hasLocation W21074853091 @default.
- W2107485309 hasOpenAccess W2107485309 @default.
- W2107485309 hasPrimaryLocation W21074853091 @default.
- W2107485309 hasRelatedWork W17407089 @default.
- W2107485309 hasRelatedWork W2057654836 @default.
- W2107485309 hasRelatedWork W2060522854 @default.
- W2107485309 hasRelatedWork W2076465614 @default.
- W2107485309 hasRelatedWork W2090869718 @default.
- W2107485309 hasRelatedWork W2129867925 @default.
- W2107485309 hasRelatedWork W2138031289 @default.
- W2107485309 hasRelatedWork W2315182454 @default.
- W2107485309 hasRelatedWork W2337271209 @default.
- W2107485309 hasRelatedWork W88323562 @default.
- W2107485309 hasVolume "111" @default.
- W2107485309 isParatext "false" @default.
- W2107485309 isRetracted "false" @default.
- W2107485309 magId "2107485309" @default.
- W2107485309 workType "article" @default.